The role of statins for primary prevention in non-elderly colorectal cancer patients

Anticancer Research

Volumn 34, Issue 9, 2014, Pages 5043-5050

  Sehdev, Amikar ^a   Shih, Y A Chen T ^b   Huo, Dezheng ^c   Vekhter, Benjamin ^d   Lyttle, Christopher ^d   Polite, Blase ^a  

^a SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Colorectal cancer; Database; MarketScan ; Non elderly; Prevention; Statin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; SIMVASTATIN; SULFONYLUREA; STATIN (PROTEIN);

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHARLSON COMORBIDITY INDEX; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; OVARY POLYCYSTIC DISEASE; PRESCRIPTION; PRIMARY PREVENTION; PRIORITY JOURNAL; AGE; COLORECTAL TUMOR; FACTUAL DATABASE; MARKETSCAN® DATABASE; MIDDLE AGED; NON-ELDERLY; PREVENTION; RISK FACTOR; UNITED STATES;

COLORECTAL CANCER; MARKETSCAN® DATABASE; NON-ELDERLY; PREVENTION; STATIN;

AGE FACTORS; CASE-CONTROL STUDIES; CHEMOPREVENTION; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK FACTORS; UNITED STATES;

EID: 84908667403     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69-90, 2011.
2. Center M, Jemal A and Smith RA: Worldwide variations in colorectal cancer. CA: A Cancer Journal for Clinicians 2009.
3. Colditz GA, Wolin KY and Gehlert S: Applying What We Know to Accelerate Cancer Prevention. Science Translational Medicine 4: 127rv124-127rv124, 2012.
4. Edwards BK, Ward E, Kohler BA and Eheman C: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and Treatment) to Reduce Future Rates. Cancer 2010.
5. Rothwell PM, Wilson M, Elwin CE, Norrving B and Algra A: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet 2010.
6. Lochhead P and Chan AT: Statins and Colorectal Cancer. Clinical Gastroenterology and Hepatology 11: 109-118, 2013.
7. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, Ward K, and Ebrahim S: Statins for the primary prevention of cardiovascular disease. Cochrane database of systematic reviews (Online) 1: CD004816, 2013.
8. Naci H, Brugts J and Ades T: Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized Controlled Trials. Circulation Cardiovascular quality and outcomes 2013.
9. Katz MS: Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nature Clinical Practice Oncology 2: 82-89, 2005.
10. Demierre M-F, Higgins PDR, Gruber SB, Hawk E and Lippman SM: Statins and cancer prevention. Nature Reviews Cancer 5: 930-942, 2005.
11. Ahnen DJ and Byers T: Editorial: Colorectal Cancer and Statins: Reflections From the End of the Road. The American Journal of Gastroenterology 104: 3024-3026, 2009.
12. Hede K: Hints That Statins Reduce Colon Cancer RiskFinally Being Put to the Test. 1-3, 2011.
13. Lee JE, Baba Y, Ng K, Giovannucci E, Fuchs CS, Ogino S and Chan AT: Statin Use and Colorectal Cancer Risk According to Molecular Subtypes in Two Large Prospective Cohort Studies. Cancer Prevention Research 4: 1808-1815, 2011.
14. Bonovas S, Filioussi K, Flordellis CS and Sitaras NM: Statins and the Risk of Colorectal Cancer: A Meta-Analysis of 18 Studies Involving More Than 1.5 Million Patients. Journal of Clinical Oncology 25: 3462-3468, 2007.
15. Bardou M, Barkun A and Martel M: Effect of statin therapy on colorectal cancer. Gut 2010.
16. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr. and Kinzler KW: Cancer genome landscapes. Science 339: 1546-1558, 2013.
17. Hachem C, Morgan R, Johnson M, Kuebeler M and El-Serag H: Statins and the Risk of Colorectal Carcinoma: A Nested Case-Control Study in Veterans With Diabetes. The American Journal of Gastroenterology 104: 1241-1248, 2009.
18. National Cancer Institute NIoH: SEER-Medicare: Calculation of Comorbidity Weights. 2010.
19. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK and Rennert G: Statins and the risk of colorectal cancer. New England Journal of Medicine 352: 2184-2192, 2005.
20. Farwell WR, Scranton RE and Lawler EV: The association between statins and cancer incidence in a veterans population. The Journal of the National Cancer Institute 2008.
21. Hoffmeister M, Chang-Claude J and Brenner H: Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. International journal of cancer Journal international du cancer 121: 1325-1330, 2007.
22. Robertson DJ, Riis AH, Friis S, Pedersen L, Baron JA and Sørensen HT: Neither Long-Term Statin Use nor Atherosclerotic Disease Is Associated With Risk of Colorectal Cancer. Clinical Gastroenterology and Hepatology 8: 1056-1061, 2010.
23. Lakha F, Theodoratou E, Farrington SM, Tenesa A, Cetnarskyj R, Din FVN, Porteous ME, Dunlop MG and Campbell H: Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer 12: 487, 2012.
24. Broughton T, Sington J and Beales IL: Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case-control study. BMC Gastroenterology 12: 1-1, 2012.
25. Blais L, Desgagné A and LeLorier J: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Archives of internal medicine 2000.
26. Graaf MR: The Risk of Cancer in Users of Statins. Journal of Clinical Oncology 22: 2388-2394, 2004.
27. Kaye JA and Jick H: Statin use and cancer risk in the General Practice Research Database. British Journal of Cancer 90: 635-637, 2004.
28. Vinogradova Y, Hippisley-Cox J, Coupland C, and Logan RF: Risk of Colorectal Cancer in Patients Prescribed Statins, Nonsteroidal Anti-Inflammatory Drugs, and Cyclooxygenase-2 Inhibitors: Nested Case-Control Study. Gastroenterology 133: 393-402, 2007.
29. Coogan PF, Rosenberg L and Strom BL: Statin use and the risk of 10 cancers. Epidemiology 2007.
30. Coogan PF, Smith J and Rosenberg L: Statin use and risk of colorectal cancer. 2007.
31. Yang Y-X, Hennessy S, Propert K, Hwang W-T, Sarkar M and Lewis JD: Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiology and Drug Safety 17: 869-876, 2008.
32. Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, and Mandelson MT: Cardiovascular medication use and risk for colorectal cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 17: 3076-3080, 2008.
33. Shadman M, Newcomb PA, Hampton JM, Wernli KJ and Trentham-Dietz A: Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World Journal of Gastroenterology 15 : 2336-2339, 2009.
34. Vinogradova Y, Coupland C and Hippisley-Cox J: Exposure to statins and risk of common cancers: a series of nested casecontrol studies. BMC Cancer 11: 409, 2011.
35. Cheng M-H: Statin use and the risk of colorectal cancer: A population-based case-control study. World Journal of Gastroenterology 17: 5197, 2011.
36. Simon MS, Rosenberg CA and Rodabough RJ: Prospective analysis of association between use of statins or other lipidlowering agents and colorectal cancer risk. Annals of Epidemiology 2012.
37. Jacobs EJ, Rodriguez C and Brady KA: Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. Journal of the National Cancer Institute 2006.
38. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP and Habel LA: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiology and Drug Safety 17: 27-36, 2008.
39. Setoguchi S, Glynn RJ, Avorn J, Mogun H and Schneeweiss S: Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. Circulation 115: 27-33, 2006.
40. Singh H, Mahmud SM, Turner D and Xue L: Long-term use of statins and risk of colorectal cancer: a population-based study. The American Journal of Gastroenterology 2009.
41. Flick ED, Habel LA, Chan KA, Haque R, Quinn VP, Van Den Eeden SK, Sternfeld B, Orav EJ, Seeger JD, Quesenberry CP and Caan BJ: Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study. Drugs 69: 1445-1457, 2009.
42. Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K and Tiihonen J: Incidence of cancer and statin usageRecord linkage study. International journal of cancer Journal international du cancer 126: 279-284, 2010.
43. Jacobs EJ, Newton CC, Thun MJ and Gapstur SM: Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer research 71: 1763-1771, 2011.
44. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sørensen HT and Olsen JH: Cancer risk among statin users: a population-based cohort study. International journal of cancer Journal international du cancer 114: 643-647, 2005.
45. Sacks FM, Pfeffer MA and Moye LA: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996.
46. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W and Gotto AM: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA: the journal of the American Medical Association 279: 1615-1622, 1998.
47. Disease) LSGL-tIwPiI: Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 359: 1379-1387, 2002.
48. Trial AOaCftACRGTAaL-LTtPHA: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA: the journal of the American Medical Association 288: 2998-3007, 2002.
49. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, Pedersen TR, Kjekshus J and Group S: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364: 771-777, 2004.
50. Group HPSC: The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC medicine 3: 6, 2005.
51. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM and Group WoSCPS: Long-term follow-up of the West of Scotland Coronary Prevention Study. The New England journal of medicine 357: 1477-1486, 2007.
52. Hsia J, MacFadyen JG, Monyak J and Ridker PM: Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol < 50 mg/dl With Rosuvastatin. JAC 57: 1666-1675, 2011.
53. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler D, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, MD LJ, FRCP LSH, FRCPC PAL, FACP PLA, MD PMG, FACP PBK, FRACP PRW, MD PZAM, MD PBF-R, MD UK, MD VO, MD PBF, MD HH, FASN PVT, FRCP PAW, FESC PDG, de Zeeuw MD PD, MD PCG-R, MRCP TD, MRCP DL, MRCP WH, MD MM, FRACP WM, MSc KW, MD PRG, MD PTP, PhD JT, FRCP PJA, BA AB, PhD CB, DPhil YC, DPhil PZC, DPhil MH, MSc CK, DPhil SP, Simpson D, MD PPS, DPhil AY, FMedSci PRC, and Investigators obotS: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. The Lancet 377: 2181-2192, 2011.